Kubota Pharmaceutical Holdings Co., Ltd. (4596.T)
JPY 57.0
(0.0%)
JPY 57.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 369 Million JPY | -21.53% |
| 2022 | 470.22 Million JPY | -30.81% |
| 2021 | 679.64 Million JPY | -2.75% |
| 2020 | 698.85 Million JPY | 5.33% |
| 2019 | 663.5 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 352.42 Million JPY | -4.78% |
| 2024 Q2 | 313.89 Million JPY | -10.93% |
| 2023 FY | 370.1 Million JPY | -21.29% |
| 2023 Q2 | 411.92 Million JPY | -7.02% |
| 2023 Q1 | 442.99 Million JPY | -5.79% |
| 2023 Q3 | 371.73 Million JPY | -9.76% |
| 2023 Q4 | 370.1 Million JPY | -0.44% |
| 2022 Q3 | 622.53 Million JPY | 0.0% |
| 2022 Q4 | 470.22 Million JPY | -24.47% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 88.635% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -481.918% |
| GNI Group Ltd. | 26.34 Billion JPY | 98.599% |
| Linical Co., Ltd. | 10.3 Billion JPY | 96.419% |
| Trans Genic Inc. | 3.81 Billion JPY | 90.321% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 37.479% |
| Soiken Holdings Inc. | 697.02 Million JPY | 47.061% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 87.784% |
| AnGes, Inc. | 2.78 Billion JPY | 86.771% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | 28.155% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.592% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -4.452% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 77.635% |
| Carna Biosciences, Inc. | 472.35 Million JPY | 21.881% |
| CanBas Co., Ltd. | 91.98 Million JPY | -301.139% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 66.258% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 54.435% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 37.851% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 91.326% |
| PeptiDream Inc. | 29.11 Billion JPY | 98.733% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 34.863% |
| Ribomic Inc. | 155.8 Million JPY | -136.828% |
| SanBio Company Limited | 2.25 Billion JPY | 83.636% |
| Healios K.K. | 11.28 Billion JPY | 96.73% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -46.855% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -52.797% |
| StemRIM | 187 Million JPY | -97.326% |
| CellSource Co., Ltd. | 677.73 Million JPY | 45.554% |
| FunPep Company Limited | 189.32 Million JPY | -94.904% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 38.186% |
| Stella Pharma Corporation | 1.44 Billion JPY | 74.439% |
| TMS Co., Ltd. | 97.68 Million JPY | -277.729% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -303.305% |
| Cuorips Inc. | 200.96 Million JPY | -83.618% |
| K Pharma,Inc. | 209.13 Million JPY | -76.442% |
| Takara Bio Inc. | 11.42 Billion JPY | 96.769% |
| ReproCELL Incorporated | 741.03 Million JPY | 50.205% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 59.791% |
| StemCell Institute Inc. | 3.85 Billion JPY | 90.417% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 59.381% |
| CellSeed Inc. | 301.04 Million JPY | -22.572% |